Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ: CRSP )

49.72 +6.23 (+14.33%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
Gold Stocks On Sale
In this video, we discuss our top stocks of the week, how gold is on sale, and how some market signals have been particularly troubling and misread. 
Via Talk Markets
Healthcare Portfolio Playbook: Time To Rebalance With MedTech
As we look to re-balance our portfolio in the near-term, investors should consider adding Medtech as we have suggested in the past. Though, more recently, we have also focused on large-cap... 
Via Talk Markets
Cramer Gives His Opinion On Bank of America, Advanced Micro Devices And More
On CNBC's "Mad Money Lightning Round," Jim Cramer said Martin Marietta Materials, Inc. (NYSE: MLM) is a well-run company. He likes the stock because it doesn't... 
Via Benzinga
CRISPR Therapeutics, Capsida Collaborate To Develop Gene-Edited Therapies For Neurological Diseases
CRISPR Therapeutics (NASDAQ: CRSP) has signed a deal with Capsida Biotherapeutics, a gene therapy player specializing in AAV engineering, to carve out a... 
Via Benzinga
Can Vertex Pharmaceuticals Recover From Its Latest Setback?
Shares of the biotech industry leader have taken a big hit thanks to a clinical development pipeline that hasn't produced any big wins lately. 
Via The Motley Fool
Why CRISPR Therapeutics Stock Is Trading Higher Today
CRISPR Therapeutics (NASDAQ:CRSP) shares are trading higher after the company and ... 
Via Benzinga
Why CRISPR Therapeutics Is Trading Higher Today
The Price And Volume Action In CRISPR Therapeutics's Stock Today CRISPR Therapeutics's (NASDAQ: 
Via Benzinga
Is It Too Late to Buy Vertex Pharmaceuticals Stock?
This biotech has likely reached its peak potential, for now. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2021
Upgrades Piper Sandler upgraded the previous rating for Boston Properties Inc (NYSE:BXP) from Neutral to Overweight. Boston Properties earned $1.56 in the first quarter,... 
Via Benzinga
10 Biggest Price Target Changes For Monday
Needham raised OrthoPediatrics Corp. (NASDAQ: KIDS) price target from $70 to $77. Vertex Pharmaceuticals shares rose 0.2% to close at $63.51 on Friday. HC Wainwright & Co.... 
Via Benzinga
Why Crispr's Gene-Editing Jump Wasn't Enough To Help Vertex Stock
Vertex Pharmaceuticals and Crispr Therapeutics appeared Friday to be making progress on a cure for two blood diseases. But only CRSP stock popped. 
Via Investor's Business Daily
Vertex, Crispr Unveil More Encouraging Data From Sickle Cell, Thalassemia Gene Therapy Trials
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Crispr Therapeutics AG (NASDAQ: CRSP) have announced new data from Phase 1/2 clinical trials... 
Via Benzinga
Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematology Association Annual Meeting
From Vertex Pharmaceuticals Incorporated
Via Business Wire
The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck
Biopharma stocks advanced in the truncated week ended June 4 amid the broader market strength. The American Society for Clinical Oncology meeting got underway during the week,... 
Via Benzinga
Exposures Product Safety
What's the Best Way to Invest in Genetics Stocks?
Here are some of our experts' favorite gene editing plays for the long run. 
Via The Motley Fool
How Much Will the Nkarta Deal Help CRISPR Therapeutics?
Unfortunately, this isn't an endorsement by a big drug developer. 
Via The Motley Fool
1 Genetics Stock to Put on Your Radar
Some of our experts think this stock has tons of long-term potential. 
Via The Motley Fool
Topics Cannabis
Exposures Cannabis
Cathie Wood's Ark Loads Up Further On Tesla And Cuts Apple Stake
Cathie Wood-led Ark Investment Management on Tuesday snapped up $27.2 million worth of shares in Tesla Inc (NASDAQ: TSLA) after a two-week gap during which shares of the... 
Via Benzinga
3 Healthcare Stocks That Might Soar if Biden Gets This Part of His Budget Approved
A new agency could help fund the attack on this chronic disease. 
Via The Motley Fool
Cathie Wood Loads Up $57M In Palantir As Stock Stages Reversal On Q1 Earnings Beat
Cathie Wood-led Ark Investment Management on Tuesday snapped up 2.8 million shares, worth about $56.7 million, in Palantir Technologies Inc (NYSE: PLTR) after the data analytics... 
Via Benzinga
ARKK Stocks Breakdowns and Bounces
After struggling for most of the past couple of months, momentum and Tech stocks are broadly outperforming today. 
Via Talk Markets
Nkarta, CRISPR Join Forces On CAR-NK Development For Cancer
Nkarta Inc (NASDAQ: NKTX) has collaborated with CRISPR Therapeutics AG(NASDAQ: CRSP) to co-develop and commercialize two CAR-NK therapies, in addition to an NK+T... 
Via Benzinga
With 1 Cure Behind It, This Breakthrough Biotech Takes Aim at a Bigger Market
One company is setting itself apart in a crowded field. 
Via The Motley Fool
This Bold Statement by the Vertex CEO Means a New Blockbuster May be Here Soon
The cystic fibrosis specialist is moving into other lucrative areas. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Will Vertex's Sickle Cell Gambit Sink bluebird bio's Stock?
The competition is starting to heat up, but bluebird is far from finished. 
Via The Motley Fool
Best Biotech Stocks & ETFs for mRNA, Gene Editing
2020 was the most challenging year in decades but it was great for scientific innovation, particularly in the biotech space. 
Via Talk Markets
The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 6) GT Biopharma, Inc. (NASDAQ:... 
Via Benzinga
Skyworks Lifts Nasdaq Ahead of Earnings; CRISPR Keeps Moving Forward
The Nasdaq gained ground to start the week. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Why Voyager Therapeutics, uniQure, Axsome, Reviva Pharma and Crispr Are Moving Today
Voyager Therapeutics, Inc. (NASDAQ: VYGR), uniQure N.V. (NASDAQ: QURE), Axsome Therapeutics, Inc. (NASDAQ: AXSM), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and CRISPR... 
Via Benzinga
2 Unstoppable Cathie Wood Stocks That Could Make You Rich
Both of these stocks have struggled in recent weeks, which means it might be a good time to initiate a position. 
Via The Motley Fool
Exposures COVID-19
< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.